B-ALL is a pernicious cancer characterized by an overproduction of immature B-cells, a vital component of the immune system responsible for antibody production. These malignant cells proliferate within the bone marrow, crowding out healthy blood cells and disseminating to other organs, including the brain, where they can evade conventional therapies. The disease commonly afflicts children, accounting for about 40% of all childhood cancers, but it also affects adults, in whom treatment outcomes are typically poorer.

Current standard-of-care approaches for B-ALL involve lengthy and intensive chemotherapy protocols spanning over two years, which, while often effective in younger patients, carry profound toxicities. Patients endure severe side effects such as immunosuppression leading to infections, bruising, bleeding, nausea, hair loss, and long-term complications affecting the nervous system, joints, and cardiac function. Alternative therapies like bone marrow transplants and CAR-T cell therapy have emerged but present their own challenges, including severe side effects, high costs, and complex logistics.

In a paper published in Nature Communications, a team led by Dr. Simon Richardson and Professor Brian Huntly has unveiled a promising new strategy employing a combination of two oral agents: venetoclax and inobrodib. Venetoclax, already approved for a related blood malignancy, acute myeloid leukemia (AML), functions by inhibiting the BCL2 protein, a key regulator of apoptosis or programmed cell death in cancerous B-cells. However, venetoclax alone shows inconsistent effectiveness against B-ALL, prompting researchers to explore mechanisms underlying resistance.

Their investigations centered on the CREBBP gene, which when mutated or inactivated, contributes to disease progression and chemotherapy resistance. CREBBP plays a crucial role in cellular metabolism and gene expression regulation. Astonishingly, the team discovered that inactivating CREBBP rewires the fat metabolism pathways within malignant B-cells. This metabolic shift sensitizes cells to death by ferroptosis — a form of programmed cell death distinct from apoptosis. Ferroptosis involves the iron-dependent peroxidation of lipids in cell membranes, which, when unchecked, leads to catastrophic cellular damage and demise.

To exploit this vulnerability, the Cambridge researchers utilized inobrodib, an inhibitor of CREBBP developed by CellCentric, a Cambridge spinout company. Through CREBBP inhibition with inobrodib, the cancer cells undergo metabolic rewiring that diminishes their ability to prevent lipid damage. When combined with venetoclax’s blockade of BCL2, this dual insult induces ferroptotic cell death in B-ALL cells, including those harboring mutations that confer resistance to venetoclax alone.

Experimental models using human and mouse B-ALL cells demonstrated that this combination therapy powerfully eradicated malignant early-stage B-cells. Notably, the therapy maintained effectiveness against genetically resilient leukemia cells, highlighting its potential to overcome existing treatment barriers. Professor Huntly emphasized the significance of these findings, noting that venetoclax and inobrodib have been safely combined in early trials for AML, bolstering hopes for rapid translation into clinical trials for B-ALL patients.

This therapeutic innovation carries several clinical advantages. Because the drugs are administered orally, the treatment paradigm could be less invasive and more convenient than current protocols. Moreover, the selective targeting of cancerous B-cells with this approach suggests fewer off-target effects, potentially sparing patients the debilitating toxicities commonly associated with chemotherapy and immunotherapies like CAR-T cells—the latter of which can irreversibly deplete normal B-cell populations, impairing immune competence.

Dr. Richardson elaborated on the immune implications, explaining that although B-cells are depleted during administration, the body’s capacity to regenerate healthy B-cells should restore immune function post-treatment. This transient effect markedly contrasts with permanent B-cell aplasia seen in CAR-T cell therapies, making venetoclax and inobrodib a potentially safer therapeutic option.

An important economic consideration accompanies this therapeutic prospect. Venetoclax’s patent expiration in the near future is anticipated to reduce its cost substantially through generics, improving accessibility and affordability for patients and healthcare systems alike. Such developments could democratize use and alleviate financial burdens associated with novel cancer therapies.

The urgency for improved B-ALL therapies is underscored by the real-life experience of survivors like Gill Murphy, who endured aggressive chemotherapy and stem cell transplant for her disease. Her story reveals the profound physical and psychological toll of current treatments, including prolonged hospitalizations and enduring side effects such as fatigue, early menopause, and cognitive challenges. Murphy’s testimony provides a poignant backdrop for the pressing need to develop more tolerable and effective treatments.

Cancer researchers have long sought strategies that not only eliminate malignant cells but also minimize collateral damage to patients’ quality of life. The Cambridge team’s discovery of ferroptosis induction via CREBBP inactivation, combined with BCL2 inhibition, represents a breakthrough in this quest. By harnessing the cancer cell’s metabolic liabilities, this approach exploits a previously untapped cell death pathway, broadening therapeutic horizons.

Despite the promising preclinical data, rigorous clinical trials are essential before this dual-drug approach can become standard treatment. The researchers are actively pursuing funding to initiate clinical trials involving adults and teenagers with B-ALL. Success in these trials could herald a new era of cancer treatment that balances efficacy with safety and patient well-being.

Beyond B-ALL, this research might also illuminate the role of ferroptosis in other hematologic malignancies and solid tumors, inspiring novel drug combinations that trigger ferroptotic cell death in resistant cancers. As scientists deepen understanding of cancer metabolism and cell death pathways, such targeted treatments could transform oncological care globally.

In conclusion, the combination of venetoclax and inobrodib leverages cutting-edge insights into genetic mutations and metabolic reprogramming to strike at the heart of B-ALL survival mechanisms. Its promise lies not only in potentially overcoming drug resistance but in offering a gentler, more precise treatment pathway that could improve survival while mitigating the physical and emotional burdens endured by patients. As research progresses, hopes rise for a future where blood cancers like B-ALL are not just treatable but conquered with compassion and precision.

Subject of Research: Animals

Article Title: CREBBP inactivation sensitizes B cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

News Publication Date: 20-May-2025

Web References: 10.1038/s41467-025-59531-6

References: Garcia-Gimenez, A, et al. CREBBP inactivation sensitizes B cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition. Nat Comms; 20 May 2025; DOI: 10.1038/s41467-025-59531-6

Keywords: Blood cancer, Leukemia, Cancer

Gastric cancer, notoriously difficult to treat due to its typically late diagnosis and aggressive nature, remains a significant global health challenge. The imperative to optimize treatment regimens to enhance tumor shrinkage prior to surgery, improve surgical outcomes, and ultimately elevate patient survival rates has driven oncologists and researchers alike to investigate innovative therapeutic combinations. This study represents a salient stride towards that goal, meticulously assessing clinical data from 409 patients who underwent radical gastrectomy with D2 lymph node dissection between 2019 and 2020.

The investigators employed robust statistical methodologies, including inverse probability weighting (IPW), to meticulously adjust for confounders and balance baseline characteristics between patients receiving XELOX combined with neoadjuvant radiotherapy (CRT group) versus those who underwent neoadjuvant chemotherapy alone (NACT group). Such rigorous analytical techniques bolster the validity of the comparative outcomes reported, lending substantive weight to the findings.

One of the most striking results centers on the pathological complete response rates observed in the two cohorts. Patients treated with the CRT regimen exhibited substantially higher rates of complete tumor eradication on pathological examination (15.8%) compared to their NACT counterparts (4.7%). This pronounced difference underscores the enhanced tumoricidal efficacy achieved through the synergistic effects of combining radiotherapy with chemotherapy prior to surgical intervention.

Further reinforcing the advantage of chemoradiotherapy, the study found a significantly higher negative conversion rate of carcinoembryonic antigen (CEA)—a critical tumor biomarker—in the CRT group (38.1%) compared to NACT patients (11.8%). This biomarker clearance potentially signals superior tumor control and may correlate with improved long-term outcomes, opening new vistas for prognostic stratification.

Concomitantly, tumor regression grading (TRG), a histopathological measure of cancer response to treatment, was markedly more favorable among patients receiving CRT. The proportion achieving TRG 0–1, indicative of minimal residual tumor cells, was over double in the CRT group (60.3% versus 24.3%), emphasizing the profound impact of integrating radiotherapy into the neoadjuvant treatment landscape.

Notably, the CRT cohort also enjoyed significantly improved downstaging of the tumor, with postoperative pathological stages ypT0 and T1 comprising 35.5% of patients, nearly tripling the rates seen with chemotherapy alone. This level of tumor downstaging can translate to more effective surgical resection and potentially better postoperative prognoses.

A curious yet clinically relevant finding emerged concerning lymph node dissection and status. Despite a lower average number of lymph nodes dissected in the CRT group (17 versus 24), the rate of pathological node negativity (ypN0) was significantly higher at 60.3%, compared to 39.8% in the NACT group. This suggests that CRT may more effectively sterilize nodal metastases, potentially lowering the burden of systemic disease.

Surgical radicality, a cornerstone for curative intent in gastric cancer surgery, was impressively achieved in both groups, with CRT enabling a 100% R0 resection rate versus 96.5% in the chemotherapy-alone cohort. Achieving R0 resection, defined as complete removal of all macroscopically and microscopically detectable tumor tissue, is critical for optimizing long-term survival in gastric cancer patients.

Importantly, despite the intensified treatment regimen, patient safety profiles between the two groups were comparable. The study meticulously evaluated perioperative complications and adverse events such as bone marrow suppression, gastrointestinal toxicities including nausea, vomiting, esophagitis, and diarrhea, finding no significant differences. This observation assuages concerns regarding the potential escalation of treatment-related morbidity when combining radiotherapy with chemotherapy.

Hospitalization times were also similar across both cohorts, suggesting that adding radiotherapy did not impose additional burdens in terms of recovery or healthcare resource utilization. The comparable safety and recovery metrics highlight that neoadjuvant chemoradiotherapy can be safely integrated into clinical practice without compromising patient quality of care or imposing undue risks.

From an oncological outcome perspective, the CRT group displayed superior disease-free survival, a vital metric reflecting the period wherein patients remain free from cancer recurrence post-treatment. However, overall survival differences did not reach statistical significance within the follow-up time frame, suggesting that longer-term studies may be necessary to unravel whether the initial disease control benefits translate into extended survival advantages.

The meticulous correlation analyses conducted between clinical variables and tumor biomarkers further enrich the understanding of prognostic factors in gastric cancer. Identifying reliable biomarkers capable of predicting response to neoadjuvant therapies remains a critical research frontier. The study’s findings advance this pursuit by delineating significant associations that could inform personalized treatment strategies in the future.

Collectively, these findings herald a paradigm shift in the management of locally advanced gastric cancer, underscoring the potential of integrating radiotherapy with the XELOX chemotherapy backbone to achieve deeper tumor regression and improved local control without compromising safety. Such evidence advocates for broader adoption of chemoradiotherapy approaches and paves the way for prospective randomized trials to consolidate these encouraging observational data.

The research team’s retrospective analysis, encompassing a substantial patient sample, provides a granular view of treatment dynamics in a real-world setting, balancing the rigor of controlled studies with pragmatic clinical insight. This approach enables a nuanced appreciation of treatment tolerability and efficacy that resonates with practicing oncologists and surgeons.

In sum, the study injects renewed optimism into the quest for enhancing neoadjuvant treatment paradigms in gastric cancer. By harnessing the complementary mechanisms of chemotherapy and radiotherapy, the combined XELOX plus neoadjuvant radiotherapy strategy emerges as a potent contender capable of amplifying tumor downstaging, bolstering pathological responses, and facilitating optimal surgical outcomes.

As the oncology community strives to refine multimodal treatment regimens, this landmark investigation lays a robust foundation for evolving guidelines and clinical decision-making. Future research endeavors will no doubt build upon these insights, potentially incorporating molecular and immunological profiling to further personalize therapy and maximize patient benefit.

Meanwhile, patients diagnosed with locally advanced gastric cancer may look forward to emerging treatment options that strategically amalgamate systemic and local therapies to surmount this formidable disease. Such advances echo the broader commitment within cancer research to transcend conventional boundaries and usher in an era of precision medicine.

The findings reported by Bu, Wang, Wang, and colleagues illuminate a promising therapeutic avenue and reaffirm the critical importance of integrating multi-disciplinary approaches to achieve superior cancer control. This harmonization of chemotherapy and radiotherapy stands poised to redefine standards of care and improve the clinical trajectory for countless individuals afflicted with gastric malignancies.

Subject of Research: Efficacy and safety comparison of XELOX chemotherapy combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy alone in locally advanced gastric cancer.

Article Title: Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer.

Article References:
Bu, S., Wang, S., Wang, T. et al. Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer. BMC Cancer 25, 731 (2025). https://doi.org/10.1186/s12885-025-14103-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14103-1